Literature DB >> 20141832

The brothers RAF.

Lawrence N Kwong1, Lynda Chin.   

Abstract

Targeted molecular therapies for cancer treatment have shown promise, but also have limitations. In this issue, Heidorn et al. (2010) find that a class of targeted molecular therapies with clinical effectiveness against one melanoma subtype may have adverse clinical effects in another. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20141832     DOI： 10.1016/j.cell.2010.01.013

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  8 in total

1.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

2.  Cancer genomics: from discovery science to personalized medicine.

Authors:  Lynda Chin; Jannik N Andersen; P Andrew Futreal
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

3.  Post-training cocaine exposure facilitates spatial memory consolidation in C57BL/6 mice.

Authors:  Sergio D Iñiguez; Sergios Charntikov; Shelley A Baella; Matthew S Herbert; Carlos A Bolaños-Guzmán; Cynthia A Crawford
Journal:  Hippocampus       Date:  2011-05-03       Impact factor: 3.899

4.  Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.

Authors:  Tuhina Mazumdar; Banibrata Sen; Yifan Wang; Shaohua Peng; Courtney Nicholas; Bonnie S Glisson; Jeffrey N Myers; Faye M Johnson
Journal:  Anticancer Drugs       Date:  2015-09       Impact factor: 2.248

5.  Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Authors:  Carmelo Nucera; Matthew A Nehs; Sushruta S Nagarkatti; Peter M Sadow; Michal Mekel; Andrew H Fischer; Paul S Lin; Gideon E Bollag; Jack Lawler; Richard A Hodin; Sareh Parangi
Journal:  Oncologist       Date:  2011-02-25

Review 6.  BRAF Mutation in Hairy Cell Leukemia.

Authors:  Ahmad Ahmadzadeh; Saeid Shahrabi; Kaveh Jaseb; Fatemeh Norozi; Mohammad Shahjahani; Tina Vosoughi; Saeideh Hajizamani; Najmaldin Saki
Journal:  Oncol Rev       Date:  2014-09-23

7.  Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.

Authors:  Shaohua Peng; Banibrata Sen; Tuhina Mazumdar; Lauren A Byers; Lixia Diao; Jing Wang; Pan Tong; Uma Giri; John V Heymach; Humam N Kadara; Faye M Johnson
Journal:  Oncotarget       Date:  2016-01-05

Review 8.  Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.

Authors:  Ufuk Degirmenci; Mei Wang; Jiancheng Hu
Journal:  Cells       Date:  2020-01-13       Impact factor: 6.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.